Opdivo is the first FDA-approved immunotherapy for the first-line treatment of gastric cancer.
Formulary Watch
Latest News
All News
Advertisement
The combination monoclonal antibody treatment of bamlanivimab and etesevimab still OK.
The new approval expands the drug's indication to include treatment in adult patients with unresectable locally advanced or metastatic triple-negative breast cancer.
Two common antidepressant and antifungal drugs were very effective at inhibiting SARS-CoV-2, the virus that causes COVID-19, according to a new study.
The novel nonstimulant medication from Supernus Pharmaceuticals can be sprinkled on food.
No adverse events reported so far.
Bristol Myers Squibb and bluebird bio’s Abecma is the first B-cell maturation antigen (BCMA)-directed CAR-T cell immunotherapy for relapsed or refractory multiple myeloma after 4 or more prior lines of therapy.
Precision medicine may mean smaller clinical trials. Collecting real-world data can help supply some of the same information as a control group.
The agency also gave the green light to Zegalogue, an injectable treatment for severe hypoglycemia.
A data monitoring committee stopped a trial early because of evidence of " profound efficacy," according to a press release issued by Vir Biotechnology and GlaxoSmithKline.
Advertisement
Companies are working on a 2-drug regimen of Gilead's lenacapavir and Merck’s islatravir.
The still-experimental oral antiviral drug has been compared to Tamiflu but would be for COVID-19 not the flu.
The decision by Roche comes shortly after AstraZeneca withdrew the bladder cancer indication for durvalumab (Imfinzi).
Application was submitted for both the 81 and 325 mg doses of the liquid-filled capsule formulation of aspirin.
Injectables are driving the growth because they can be taken less frequently and adherence is a problem with oral medications.
The FDA approved the use of Entresto in a broader group of heart failure patients that includes a large percentage of those with preserved ejection fraction.
Application to the FDA is based on results from a placebo-controlled trial showing a 15% decrease in body weight among those who are obese or overweight.
One of the new treatments available is a CAR-T cell therapy to treat relapsed or refractory large B-cell lymphoma.
Preliminary results from a safety clinical trial show an increased risk of serious heart-related problems and cancer with the rheumatoid arthritis and ulcerative colitis medicine Xeljanz.
Aurinia’s Lupkynis, used in combination with a background immunosuppressive therapy regimen, is available now.
FDA approves first complete long-acting HIV-1 treatment
FDA cleared cabozantinib (Cabometyx) for patients with advanced renal cell carcinoma as a first-line treatment in combination with nivolumab (Opdivo).
Advertisement
Advertisement
